Skip to Content
Biotechnology

Immunity to covid-19 could disappear in months, a new study suggests

How long are people protected from re-infection? It's one of the biggest questions of the pandemic.
Unsplash

The lowdown: Immunity to covid-19 may be short-lived, according to a new longitudinal study of people who have caught the disease and recovered.

The study: Researchers at King’s College London repeatedly tested 96 patients and health-care workers at Guy’s and St Thomas’ NHS Foundation Trust for antibodies between March and June. All the participants were confirmed to have had covid-19, either via a PCR test or a positive antibody test. The researchers found that levels of virus-fighting antibodies peaked about three weeks after symptoms started and then rapidly fell away. Although 60% of participants produced a “potent” antibody response while they had covid-19, only 17% had the same level of potency at the end of the three-month testing period. Antibody levels were higher and longer-lasting in people who had had more severe cases of covid-19. For some milder cases, it was impossible to detect any antibodies at all at the end of the three months. The research is published in a preprint paper in medRxiv, which means the findings have yet to be subjected to peer review.

What it means: The study raises the prospect that, like other coronaviruses, covid-19 could reinfect people repeatedly. If that’s the case, “herd immunity” may never arrive, either through a one-shot vaccine or through community spread of the virus, as any protective antibodies would wane with time. However, antibodies are not the only way people can fight off covid-19. T cells, which seek and destroy cells infected with SARS-CoV-2, could also provide some protection. In short, we have not yet generated enough data from patients to be able to draw conclusions on immunity with a high degree of certainty. There have been anecdotal reports of people catching covid-19 for a second time, but none have been confirmed.

Deep Dive

Biotechnology

These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.